Novartis’ spring TV campaign for breast cancer drug Kisqali featured a first-ever real patient spokesperson, and now the pharma is sharing even more stories this month. The new social media work highlights two additional patients — Rose and Dee — in videos talking about their experiences with metastatic breast cancer (MBC). The latest effort is a collaboration with People magazine, BreastCancer.org and Healthline and continues Novartis’ Kisqali DTC campaign theme of people living with MBC as “thrivers.”

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

I hope your weekend is off to a nice start, wherever you are reading this email. As for me, I’m trying to catch the tail of the Lunar New Year festivities.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

While mRNA took center stage at yesterday’s FDA vaccine advisory committee meeting, Novavax announced its plans to deliver an updated protein-based vaccine based on new guidance.

Vaccines and Related Biological Products Advisory Committee (VRBPAC) members voted unanimously in favor of “harmonizing” Covid vaccine compositions, meaning all future vaccine recipients would receive a bivalent vaccine, regardless of whether they’ve gotten their primary series.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

When it comes to customer service to healthcare professionals, pharma companies’ overall average rating is, well, average. Its industry customer experience score of 59 is at the lower end of “good” (rated as scores from 51-75) in DT Consulting’s annual assessment out now.

Topping the list of individual pharma companies was UCB with a 66 score on the consultant’s proprietary “Customer Experience Quotient” or CXQ scale. Novo Nordisk and Gilead Sciences followed, tied for second at 65, while Boehringer Ingelheim and Johnson & Johnson’s Janssen tied for third with 64. Still, none of the top scores neared “excellent” territory of 76 or higher.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Massachusetts-based iVexSol has secured funding to the tune of $23.8 million in its latest Series A round. The new investors include Bristol Myers Squibb, manufacturer Charles River Laboratories and Asahi Kasei Medical.

iVexSol is a manufacturer of lentiviral vectors (LVV), used in making gene therapies, and this latest round of fundraising brings its total Series A total over $39 million, which will be used to recruit more employees and bolster its technology.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN